Summary
This phase II/III trial evaluated neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer, a population with limited therapeutic options. The study assessed efficacy endpoints including pathological response and safety outcomes in patients who cannot tolerate standard cisplatin-based chemotherapy. Results are presented as final outcomes from this multicentre international trial.
UK applicability
This trial likely enrolled UK sites given the multinational authorship and publication in European Urology; findings would be directly applicable to UK clinical practice for treatment of ineligible muscle-invasive bladder cancer patients. However, NHS funding and access to atezolizumab would depend on NICE appraisal and commissioning decisions.
Key measures
Pathological complete response rate, clinical response rate, adverse event rates, progression-free survival, overall survival
Outcomes reported
The study reported efficacy and safety outcomes of neoadjuvant atezolizumab (a PD-L1 inhibitor) in cisplatin-ineligible patients with muscle-invasive urothelial bladder cancer. Clinical response rates, pathological complete response rates, and adverse events were assessed.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.